Market Overview

UPDATE: McNicoll Lewis Vlak Initiates Galena Biopharma at Buy on Cancer Vaccine Potential

Related GALE
Midday Gainers From Wednesday, August 27
UPDATE: MLV & Co Reiterates On Galena Biopharma On Positive Long-Term Outlook

McNicoll Lewis Vlak initiated coverage on Galena Biopharma (NASDAQ: GALE) with a Buy rating and a $6 price target.

McNicoll Lewis Vlak commented, "As we near the end of Breast Cancer Awareness month, we are initiating coverage on Galena Biopharma Inc. with a BUY recommendation and one-year price target of $6.00 based on the company's lead Phase III asset, a cancer vaccine called NeuVax. An ongoing Phase III trial, being conducted under a Special Protocol Assessment (SPA), is targeting breast cancer patients who are classified as HER2/neu negative but have node-positive disease. Breast cancer affects one in eight women, and we believe NeuVax will be able to prolong the lives of those who are fortunate enough to catch their disease early."

Galena Biopharma closed at $1.88 on Wednesday.

Latest Ratings for GALE

DateFirmActionFromTo
Mar 2014McNicoll Lewis VlakMaintainsBuy
Feb 2014Cantor FitzgeraldDowngradesBuySell
Nov 2013OppenheimerInitiates Coverage onOutperform

View More Analyst Ratings for GALE
View the Latest Analyst Ratings

Posted-In: mcnicoll lewis vlakAnalyst Color Initiation Intraday Update Analyst Ratings

 

Related Articles (GALE)

Around the Web, We're Loving...

Partner Network

Get Benzinga's Newsletters